Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Strategies for Liver Transplantation in Liver Cancers
share announcement

Strategies for Liver Transplantation in Liver Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: closed (20 April 2022) | Viewed by 5264

Special Issue Editor

Prof. Alfonso W. Avolio

E-Mail Website
Guest Editor
Dipartimento di scienze mediche e chirurgiche, Chirurgia Generale e del Trapianto di Fegato, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy
Interests: Liver transplantation; hepatocellular carcinoma; cholangiocarcinoma; liver metastasis; donor–recipient match in liver transplantation; early graft failure after liver transplantation; immunosuppression in the liver transplanted patient
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Indications for liver transplantation (LT) are changing. Until now, patients with post-hepatitis C (HCV) constituted more than a third of LT cases. Today, only a minority of HCV patients are listed for transplantation. In fact, direct-acting antiviral treatments are highly efficacious in preventing HCV-related liver disease progression. Likewise, the number of candidates with neoplastic disease is progressively expanding, thanks to the implementation of donation after cardiac death and the widespread use of perfusion machines, which can rescue grafts from high-risk fatty donors. Moreover, the practice of living donor transplantation is progressively spreading.

We are adopting a less restrictive approach to list hepatocellular carcinoma patients (patients with a higher tumor burden), while offering LT to patients with unresectable metastases from colorectal adenocarcinomas, or unresectable hilar cholangiocarcinoma. Actually, knowledge in these settings is limited and well-designed studies are highly needed.

In this Special Issue of Cancers, experts in novel indications for LT, either in primary or secondary liver cancers, will summarize current approaches. 

Prof. Alfonso W. Avolio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Liver transplantation
  • Hepatocellular carcinoma
  • Hilar cholangiocarcinoma
  • Liver Metastases from colorectal adenocarcinomas

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1120 KiB  
Article
Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling
by Salvatore Gruttadauria, Floriana Barbera, Duilio Pagano, Rosa Liotta, Roberto Miraglia, Marco Barbara, Maria Grazia Bavetta, Calogero Cammà, Ioannis Petridis, Daniele Di Carlo, Pier Giulio Conaldi and Fabrizio Di Francesco
Cancers 2021, 13(23), 6049; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13236049 - 01 Dec 2021
Cited by 3 | Viewed by 2031
Abstract
Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive primary liver tumor, characterized by a range of different clinical manifestations and by increasing incidence and mortality rates even after curative treatment with radical resection. In recent years, growing attention has been devoted to this [...] Read more.
Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive primary liver tumor, characterized by a range of different clinical manifestations and by increasing incidence and mortality rates even after curative treatment with radical resection. In recent years, growing attention has been devoted to this disease and some evidence supports liver transplantation (LT) as an appropriate treatment for intrahepatic cholangiocarcinoma; evolving work has also provided a framework for better understanding the genetic basis of this cancer. The aim of this study was to provide a clinical description of our series of patients complemented with Next-Generation Sequencing genomic profiling. From 1999 to 2021, 12 patients who underwent LT with either iCCA or a combined hepatocellular and cholangiocellular carcinoma (HCC-iCCA) were included in this study. Mutations were observed in gene activating signaling pathways known to be involved with iCCA tumorigenesis (KRAS/MAPK, P53, PI3K-Akt/mTOR, cAMP, WNT, epigenetic regulation and chromatin remodeling). Among several others, a strong association was observed between the Notch pathway and tumor size (point-biserial rhopb = 0.93). Our results are suggestive of the benefit potentially derived from molecular analysis to improve our diagnostic capabilities and to devise new treatment protocols, and eventually ameliorate long-term survival of patients affected by iCCA or HCC-iCCA. Full article
(This article belongs to the Special Issue Strategies for Liver Transplantation in Liver Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

32 pages, 452 KiB  
Review
Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation
by Filippo Pelizzaro, Martina Gambato, Enrico Gringeri, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Patrizia Burra and Francesco Paolo Russo
Cancers 2021, 13(19), 4882; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13194882 - 29 Sep 2021
Cited by 15 | Viewed by 2690
Abstract
Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT), occurring in 10–15% of cases, is a major concern. A lot of work has been done in order to refine the selection of LT candidates with HCC and to improve the outcome of patients [...] Read more.
Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT), occurring in 10–15% of cases, is a major concern. A lot of work has been done in order to refine the selection of LT candidates with HCC and to improve the outcome of patients with recurrence. Despite this, the prognosis of these patients remains poor, partly due to the several areas of uncertainty in their management. Even if surveillance for HCC recurrence is crucial for early detection, there is currently no evidence to support a specific and cost-effective post-LT surveillance strategy. Concerning preventive measures, consensus on the best immunosuppressive drugs has not been reached and not enough data to support adjuvant therapy are present. Several therapeutic approaches (surgical, locoregional and systemic treatments) are available in case of recurrence, but there are still few data in the post-LT setting. Moreover, the use of immune checkpoint inhibitors is controversial in transplant recipients considered the risk of rejection. In this paper, the available evidence on the management of HCC recurrence after LT is comprehensively reviewed, considering pre- and post-transplant risk stratification, post-transplant surveillance, preventive strategies and treatment options. Full article
(This article belongs to the Special Issue Strategies for Liver Transplantation in Liver Cancers)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop